BeiGene (BGNE) said Monday that BGB-16673, received a fast track designation from the US Food and Drug Administration for potentially treating relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
The designation, with support from phase 1/2 safety and efficacy data, is to expedite FDA's review of BGB-16673 as a treatment for adults with CLL or SLL that has relapsed or did not respond to initial treatment, according to BeiGene.
Shares of the company were up 2.8% in recent Monday premarket activity.
Price: 199.23, Change: +5.41, Percent Change: +2.79
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。